Study of a new drug after chemoradiation for limited-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new medication, HS-20093, to see if it can help people with limited-stage small cell lung cancer who have completed chemoradiation but cannot have surgery. The drug is given as an extra treatment after the standard therapy to try to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have limited-stage small cell lung cancer, and you are not having surgery (either because it's not an option or you choose not to).
- You have finished chemoradiation (chemotherapy plus radiation) and the cancer has not grown.
- You need to be in good general health, able to care for yourself, and have a life expectancy of more than 12 weeks.
- You must agree to use effective birth control during the study, and if you are a woman, you cannot be pregnant.
- You must not have certain other medical conditions like interstitial lung disease, serious heart problems, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of two experimental drugs for people with limited-stage small cell lung cancer that hasn't gotten worse after standard treatment with chemotherapy and radiation. The goal is to see if this combination can help control the cancer for a longer time.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
This trial tests a new combination of investigational drugs (HS-20093) for people with extensive-stage small cell lung cancer whose disease hasn't progressed after initial treatment. The goal is to see if this approach can keep the cancer from growing.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.